These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34387605)

  • 61. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
    Gaudet M; Vigneault É; Foster W; Meyer F; Martin AG
    Radiother Oncol; 2016 Jan; 118(1):141-7. PubMed ID: 26702991
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
    Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
    Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
    Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
    Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
    [No Abstract]   [Full Text] [Related]  

  • 67. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
    J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Taneja SS
    J Urol; 2013 Sep; 190(3):880. PubMed ID: 23931194
    [No Abstract]   [Full Text] [Related]  

  • 72. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
    Wirth MP; Hakenberg OW; Froehner M
    Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
    Nadal R; McMahan ZH; Antonarakis ES
    Clin Genitourin Cancer; 2013 Dec; 11(4):e15-23. PubMed ID: 23820064
    [No Abstract]   [Full Text] [Related]  

  • 74. Oral bicalutamide for female pattern hair loss: A pilot study.
    Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
    Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
    [No Abstract]   [Full Text] [Related]  

  • 75. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
    Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
    Int J Urol; 2017 Dec; 24(12):861-862. PubMed ID: 28895205
    [No Abstract]   [Full Text] [Related]  

  • 76. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-androgens and other hormonal therapies for prostate cancer.
    Richie JP
    Urology; 1999 Dec; 54(6A Suppl):15-8. PubMed ID: 10606279
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bicalutamide (Casodex) in the treatment of prostate cancer.
    Fradet Y
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):37-48. PubMed ID: 14748655
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate cancer tissue is masked by bicalutamide: a case report.
    Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC
    Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
    Sternberg CN
    BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.